Celldex Announces Phase 2 Results For Barzolvolimab In Chronic Inducible Urticaria; Achieves Primary Endpoint With Significant Complete Response Rates In Both Dose Groups
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics announced positive Phase 2 results for Barzolvolimab in treating Chronic Inducible Urticaria, achieving primary endpoints with significant complete response rates. The company plans to move forward with Phase 3 registration development.
July 29, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics announced successful Phase 2 results for Barzolvolimab in treating Chronic Inducible Urticaria, achieving primary endpoints with significant complete response rates. The company plans to proceed with Phase 3 registration development.
The successful Phase 2 results and the plan to move forward with Phase 3 development are likely to positively impact Celldex's stock price in the short term. Achieving primary endpoints in a large, randomized, placebo-controlled study demonstrates the drug's potential efficacy, which is a significant milestone for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100